Shin Nippon Biomedical Laboratories, Ltd.

DB:YB3 Stock Report

Market Cap: €386.5m

Shin Nippon Biomedical Laboratories Future Growth

Future criteria checks 2/6

Shin Nippon Biomedical Laboratories is forecast to grow earnings and revenue by 9.7% and 7.3% per annum respectively. EPS is expected to grow by 12.5% per annum. Return on equity is forecast to be 12.1% in 3 years.

Key information

9.7%

Earnings growth rate

12.5%

EPS growth rate

Life Sciences earnings growth26.2%
Revenue growth rate7.3%
Future return on equity12.1%
Analyst coverage

Low

Last updated20 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:YB3 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202735,2644,900-1,1092,9131
3/31/202632,3934,240-2,1031,9191
3/31/202529,3283,292-10,2403411
9/30/202427,0743,896-11,7241,650N/A
6/30/202426,1954,280N/AN/AN/A
3/31/202426,4505,531-6,4982,106N/A
12/31/202326,7035,503N/AN/AN/A
9/30/202326,6264,607-4,0741,899N/A
6/30/202326,8485,489N/AN/AN/A
3/31/202325,0906,060-9504,004N/A
12/31/202221,1736,231N/AN/AN/A
9/30/202220,1358,0434,3827,170N/A
6/30/202218,7537,245N/AN/AN/A
3/31/202217,7487,1274,3395,952N/A
12/31/202117,6367,432N/AN/AN/A
9/30/202116,0686,0254,0755,301N/A
6/30/202114,9784,844N/AN/AN/A
3/31/202115,1103,6613,6294,746N/A
12/31/202014,9102,421N/AN/AN/A
9/30/202015,1752,8121,3892,706N/A
6/30/202015,0043,234N/AN/AN/A
3/31/202014,5612,5501,7883,018N/A
12/31/201913,4971,990N/AN/AN/A
9/30/201913,1671,9151,7842,988N/A
6/30/201914,6761,524N/AN/AN/A
3/31/201915,6581,9501,7942,892N/A
12/31/201817,337-49N/AN/AN/A
9/30/201817,928-9931,6312,943N/A
6/30/201816,937-2,566N/AN/AN/A
3/31/201816,600-3,555N/A1,344N/A
12/31/201717,186-1,072N/AN/AN/A
9/30/201717,714327N/A280N/A
6/30/201717,230260N/AN/AN/A
3/31/201717,244-915N/A-849N/A
12/31/201615,880-1,821N/AN/AN/A
9/30/201615,269-1,273N/A-3,109N/A
6/30/201614,922-1,475N/AN/AN/A
3/31/201614,7502,646N/A-3,339N/A
12/31/201515,6372,060N/AN/AN/A
9/30/201516,344401N/A-2,379N/A
6/30/201517,1641,546N/AN/AN/A
3/31/201517,835-1,385N/A-2,156N/A
12/31/201418,058-417N/AN/AN/A
9/30/201417,161-599N/A-1,377N/A
6/30/201417,132-1,074N/AN/AN/A
3/31/201416,926-754N/A-1,620N/A
12/31/201316,993-1,443N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: YB3's forecast earnings growth (9.7% per year) is above the savings rate (1%).

Earnings vs Market: YB3's earnings (9.7% per year) are forecast to grow slower than the German market (21.1% per year).

High Growth Earnings: YB3's earnings are forecast to grow, but not significantly.

Revenue vs Market: YB3's revenue (7.3% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: YB3's revenue (7.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: YB3's Return on Equity is forecast to be low in 3 years time (12.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y